Back to Journals » Therapeutics and Clinical Risk Management » Volume 11

Emerging therapeutic options for sporadic inclusion body myositis

Authors Alfano L, Lowes LP

Received 29 July 2015

Accepted for publication 30 August 2015

Published 25 September 2015 Volume 2015:11 Pages 1459—1467


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Professor Garry Walsh

Lindsay N Alfano, Linda P Lowes

Nationwide Children’s Hospital, Center for Gene Therapy, Columbus, OH, USA

Abstract: Sporadic inclusion body myositis is the most common inflammatory muscle disorder preferentially affecting males over the age of 40 years. Progressive muscle weakness of the finger flexors and quadriceps muscles results in loss of independence with activities of daily living and eventual wheelchair dependence. Initial signs of disease are often overlooked and can lead to mis- or delayed diagnosis. The underlying cause of disease is unknown, and disease progression appears refractory to available treatment options. This review discusses the clinical presentation of inclusion body myositis and the current efforts in diagnosis, and focuses on the current state of research for both nonpharmacological and pharmacological treatment options for this patient group.

Keywords: myositis, inclusion body myositis, inflammatory myopathy, treatment, function, outcomes

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]